Defects in transcriptional regulators of pancreatic exocrine differentiation have been implicated in pancreatic tumorigenesis, but the molecular mechanisms are poorly understood. The locus encoding the transcription factor HNF1A harbors susceptibility variants for pancreatic ductal adenocarcinoma (PDAC), while KDM6A, encoding the histone demethylase UTX, carries somatic mutations in PDAC. Here, we show that pancreas-specific Hnf1a null mutations phenocopy Utx deficient mutations, and both synergize with Kras G12D to cause PDAC with sarcomatoid features. We combine genetic, epigenomic and biochemical studies to show that HNF1A recruits UTX to genomic binding sites in pancreatic acinar cells. This remodels the acinar enhancer landscape, activates a differentiation program, and indirectly suppresses oncogenic and epithelial-mesenchymal transition genes. Finally, we identify a subset of non-classical PDAC samples that exhibit the HNF1A/UTX-deficient molecular phenotype. These findings provide direct genetic evidence that HNF1A-deficiency promotes PDAC. They also connect the tumor suppressive role of UTX deficiency with a cell-specific molecular mechanism that underlies PDAC subtype definition.
Results

Hnf1a-deficiency promotes Kras-induced oncogenesis.
To directly test the role of Hnf1a in pancreatic carcinogenesis, we created a conditional Hnf1a loss of function allele (Hnf1a LoxP ) ( Supplementary Figure 1a) and used a Pdx1 Cre transgene to delete Hnf1a in all pancreatic epithelial lineages (hereafter referred to as Hnf1a pKO mice, Supplementary Figure 1b) . HNF1A is normally expressed in pancreatic acinar and endocrine cells, but not in duct cells 28 , and Hnf1a pKO mice showed disrupted HNF1A expression in both acinar and endocrine cells (Supplementary Figure 1c) . As expected from previous studies of Hnf1a germ-line null mutants, this did not produce gross defects in pancreas organogenesis, although acinar cells displayed signs of markedly increased proliferation 25, [29] [30] [31] (Figure 1a) .
To determine whether Hnf1a interacts with Kras-induced carcinogenesis, we created mice with combined conditional Hnf1a and Kras G12D mutations, hereafter referred to as Hnf1a pKO ;Kras G12D mice (Supplementary Figure 1d) . In the absence of Hnf1a mutant alleles, Pdx1 Cre -induced Kras G12D activation expectedly gave rise to occasional low-grade PanINs or acinar-to-ductal metaplasia (ADM) lesions by 2 months of age 32 , (Figure 1b , e, h, k, and n). Hnf1a pKO ;Kras G12D mice showed no lesions at 7 days of age (Figure 1c-d ), yet by weaning they had already developed focal ADM and desmoplastic reactions, which became more prominent as the mice aged (Figure 1f-g and Figure 1i -j). Eight-week-old Hnf1a pKO ;Kras G12D mice additionally showed non-invasive atypical tubular complexes, higher-grade PanINs with luminal budding, desmoplastic reaction and foci of spindle cell (mesenchymal) proliferation, some of which showed incipient infiltrative growth (Figure 1lm and Figure1o-p) . These findings indicate that pancreatic Hnf1a-deficiency cooperates with Kras to promote sarcomatoid forms of PDAC.
Hnf1a activates an acinar differentiation program that inhibits oncogenic programs. To understand how Hnf1a-deficiency promotes pancreatic cancer, we examined the transcriptional programs controlled by Hnf1a in pancreatic exocrine cells. Genetic lineage tracing studies in mice have shown that, despite the ductal morphology of PDAC, Kras G12Dinduced PDAC can originate from acinar cells that undergo ADM and PanIN, contrasting with intraductal papillary mucinous neoplasms that arise from duct cells 33, 34 . We therefore used a Ptf1a Cre allele, which ensured high efficiency recombination of Hnf1a in mouse acinar cells, and more limited recombination in endocrine cells (Ptf1a Cre ; Hnf1a LoxP/LoxP ; hereafter referred to as Hnf1a aKO ) ( Supplementary Figure 2a and 2b) . Eight-week-old Hnf1a aKO mice were normoglycemic, and like Hnf1a pKO mice showed normal pancreatic histology (Supplementary Figure 2c) . We profiled transcripts in pancreas from 8-week-old Hnf1a aKO mice and, despite the normal histology, found profound transcriptional changes (Figure 2a,  Supplementary Table 1 ). We observed decreased expression of genes specific to differentiated acinar cells, including Ptf1a, Pla2g1b, Serpini2 and Ctrb1 (Figure 2b and  Supplementary Figure 2d ), and increased expression of genes specific to pancreatic mesenchymal cells (Figure 2b, Supplementary Table 2 ). Downregulated genes were enriched in metabolic processes such as inositol phosphate turnover, amino acid metabolism, and protection against oxidative stress, whereas upregulated genes were enriched in annotations associated with the extracellular matrix (collagen formation, ECM-receptor interactions, integrin cell surface interactions) and complement activation (Figure 2c , Supplementary Table 2 ). We also observed activation of known oncogenic programs such as EMT, RAS, PI3K-AKT, STAT3, MAPK, and WNT signaling, cell cycle related pathways, and cholesterol biosynthesis (Figure 2d, Supplementary Figure 2e , Supplementary Table  2 ).
To assess which of these transcriptional changes reflects a direct function of HNF1A in acinar cells, we profiled genome-wide binding sites of HNF1A in adult pancreas, as well as H3K27 acetylation to mark active enhancers and promoters (Supplementary Figure 2f) . HNF1Abound genomic regions had canonical HNF1 recognition sequences in 405 out of the top 500 most significant binding sites (81%), confirming the specificity of the assay (Supplementary  Figure 2g) , and they were expectedly enriched in enhancers and promoters ( Supplementary  Figure 2h ). HNF1A binding was specifically enriched amongst genes that showed downregulation in Hnf1a aKO pancreas (odds ratio = 3.6 relative to all other genes, P = 10 -22 , Figure 2e ). This was consistent with HNF1A acting as an essential positive regulator of some of the genes to which it binds. HNF1A binding was, however, not enriched in genes that were upregulated in Hnf1a aKO pancreas, compared with active genes that did not show altered regulation (odds ratio = 0.4, P=N.S; Figure 2e, Supplementary Figure 2i) . These studies, therefore, uncovered direct HNF1A-dependent genetic programs. They show that the function of HNF1A in pancreatic acinar cells entails direct transcriptional activation of a broad differentiated cell program that controls metabolic functions. They also revealed that HNF1A suppresses growth promoting pathways and that, given the absence of enriched HNF1A binding to upregulated genes, this is largely mediated through indirect regulatory mechanisms.
Deregulation of the HNF1A-dependent program in non-classical PDAC.
To explore the role of HNF1A-dependent programs in human PDAC, we asked if deregulated genes from Hnf1a aKO pancreas exhibit altered expression in human PDAC primary tumors. We thus examined transcriptome data from the TCGA-PAAD study 35 . We defined human orthologs of genes that showed significant down or upregulation in Hnf1a aKO pancreas, and found that these gene sets showed concordant down or upregulation in non-classical tumor molecular subtypesvariously defined as quasimesenchymal, basal, and squamous-like PDAC 3, 36, 37 (Figure 3a) . We also employed the same gene sets to cluster human tumor samples from TCGA-PAAD and ICGC-PACA cohorts 3 , using non-negative matrix factorization. This exposed a cluster of predominantly non-classical tumors that showed transcriptional changes in the same direction as Hnf1a aKO pancreas (HNF1A cluster 3, Supplementary Figure 3a) .
We next sought to identify tumors with most pronounced HNF1A-deficient function. Because our findings showed that HNF1A primarily functions as a direct activator, we defined tumors with most pronounced downregulation of genes that were both HNF1A-bound and downregulated in Hnf1a mutant mice (hereafter referred to as HNF1A loss of function, or HNF1A LoF tumors). We found that HNF1A LoF tumors showed a remarkable concordance with tumors that were consistently classified as non-classical molecular subtypes in independent studies, and were therefore significantly enriched in quasimesenchymal (Fisher's P = 1.7x10 -14 ), basal (P = 2.9x10 -6 ), and squamous-like (P = 1.1x10 -9 ) subtypes ( Figure 3b ). They also had increased TP63 mRNA, a marker of squamous-like PDAC 3, 15, 38 (Supplementary Figure 3b) .
HNF1A LoF tumorsas well as non-classical PDACshowed significantly lower HNF1A mRNA levels (Kruskall Wallis P = 0.0064), although there was considerable overlap with control tumors, suggesting that abnormal HNF1A function cannot be exclusively explained by differences in HNF1A expression (Figure 3c, Supplementary Figure 3c ). Furthermore, although HNF1A LoF tumors had non-classical molecular signatureswhich correlate with high histological grade -HNF1A immunoreactivity was not significantly lower in high histological grade (poorly differentiated) tumors in tissue microarrays of human PDAC (n=102) (Supplementary Figure 3e) . These results reveal abnormal HNF1A function in a subset of non-classical PDAC tumors.
HNF1A-dependent changes in UTX-deficient non-classical PDAC.
Although a subset of non-classical PDAC samples exhibit a gene expression profile that resembles that of pancreatic Hnf1a-mutant mice, HNF1A mRNA levels were not invariably altered, and so far recurrent somatic HNF1A mutations have not been reported in PDAC. This raised the question of why non-classical PDAC shows abnormal HNF1A function. Non-classical (e.g. squamous-like) PDAC have been shown to express low UTX mRNA, and are enriched in UTX somatic genomic defects 3, 15 . Our studies also showed decreased UTX mRNA in nonclassical PDAC (P < 10 -3 ) (Supplementary Figure 3d ) and decreased UTX immunoreactivity in poorly differentiated tumors (P = 0.03, n=94) (Supplementary Figure  3f) . Importantly, tumors with HNF1A LoF phenotypes showed decreased UTX mRNA (median [IQR]: 41.9 [32.2-50.5] (Figure 3d) . Furthermore, the analysis of genotypes from the Australian ICGC-PACA study revealed putative loss of function UTX mutations in 19% of tumors showing HNF1A LoF phenotypes, compared with 2% of all other tumors (Fisher's P = 0.005) (Figure 3b) . Likewise, tumors with UTX putative loss of function mutations showed abnormal HNF1A-dependent programs (Figure 3b) . Collectively, these correlations hinted at a mechanistic link between UTX-and HNF1A-deficient phenotypes in non-classical PDAC.
Utx-dependent Kras-induced oncogenesis.
To examine the relationship between Hnf1a-and Utx-deficiency in pancreatic cancer, we generated mice with pancreas-specific inactivating Utx mutations and oncogenic Kras mutations (Pdx1 Cre , Utx LoxP/LoxP , Kras G12D , hereafter referred to as Utx pKO ;Kras G12D mice; (Supplementary Figure 4a-c) . We focused on female mice because UTX is encoded in the X chromosome, and males harbor a Y chromosome paralog named Uty. Utx pKO ;Kras G12D mice showed normal pancreas morphology at 7 days of age (Figure 4a-c Figure 4d ). This contrasted with 8 week-old control Kras G12D mice, which expectedly only presented occasional acinar-to-ductal metaplasia (Figure 4j and m). This finding was consistent with recently reported findings in 6 week-old mice 15 . Male mice presented delayed mortality compared to females, suggesting partial Uty compensatory tumor suppressor functions, as reported previously 15, 39 . These findings, therefore, showed Utxdependent sarcomatoid PDAC lesions that are reminiscent of those observed in Hnf1a pKO ;Kras G12D mice, although Utx-deficient tumors showed earlier age of onset and more rapid growth. These results were consistent with the overlapping UTX-and HNF1A-deficient molecular signatures of human tumors.
UTX activates a growth-suppressing program of differentiated acinar cells. The analysis of molecular signatures in human tumors, and the semblance of mouse genetic phenotypes, suggested that UTX and HNF1A might control common tumor suppressive programs in pancreatic exocrine cells. We thus studied the transcriptional function of UTX in non-tumoral, differentiated pancreatic exocrine cells, following a strategy similar to that described above for HNF1A. We examined female Utx pKO mice, in which the Pdx1 Cre transgene led to pancreatic inactivation of Utx in most cells from all pancreatic epithelial lineages (>98% of which are exocrine cells) as early as e15.5 (Supplementary Figure 5a) , and a marked reduction of UTX protein at weaning (Supplementary Figure 4c) .
Utx pKO mice were born at the expected Mendelian ratio and appeared healthy. They had normal glycemia at 12 weeks of age ( Supplementary Figure 5b ) and unaltered pancreas morphology at birth and until weaning, indicating that, like HNF1A, UTX is dispensable for pancreas organogenesis (Supplementary Figure 5c-f) . In analogy to observations in Hnf1a aKO mice, acinar cells showed increased proliferation at weaning ( Supplementary  Figure 5i ). Unlike Hnf1a aKO mice, as Utx pKO female mice aged they showed acinar cell attrition, and by 8 weeks of age some atrophic pancreatic lobules could be observed ( Supplementary Figure 5g-h) .
To assess the transcriptional function of UTX in the pancreas, we analyzed pancreatic RNA from 4-day old female Utx pKO mice, prior to the development of any morphological acinar cell abnormalities. This revealed profound transcriptional changes, with downregulation of acinar-specific genes (but not duct-or islet-genes) and upregulation of mesenchymal genes (Figure 5a , b, Supplementary Table 3 ). Downregulated genes were associated with metabolic pathways including glutathione, peptide hormone, ether lipid metabolism, and NRF2 (antioxidant) metabolism (Figure 5c ). Upregulated genes in Utx pKO mice were enriched in programs regulating cholesterol biosynthesis, extracellular matrix organization and the innate immune response (Fc gamma R-mediated phagocytosis). GSEA showed prominent enrichment in additional annotations related to oncogenic pathways, including EMT, Wnt, ErbB, MAPK, onctostatin M, and NFKB signaling (Figure 5d , Supplementary Figure 5j , Supplementary Table 4 ). The biological pathways that were down-and upregulated in Utx pKO mice were generally deregulated in the same direction as in Hnf1a aKO (Supplementary Figure 5k , Supplementary Table 5 ). These observations suggested that Utx could exert its tumor suppressor function in acinar cells through the regulation of broadly similar pathways as Hnf1a, namely through the maintenance of acinar differentiated cell programs and inhibition of growth-promoting pathways.
Shared transcriptomes in Utx pKO mice and UTX-mutant human PDAC. We assessed the relevance of the transcriptional phenotype of Utx pKO pancreas to human PDAC. GSEA showed that up-and downregulated genes from tumors with UTX putative loss of function mutations were concordantly up-and downregulated in Utx pKO pancreas ( Supplementary  Figure 5l ). Furthermore, low UTX mRNA was observed in human tumors that showed greatest deregulation of genes downregulated in Utx pKO pancreas ( Supplementary  Figure5m) . Likewise, non-classical PDAC tumors, which exhibit decreased UTX expression, showed down-and up-regulation of deregulated genes in Utx pKO pancreas (FDR q = 10 -4 and 0.04, respectively; Supplementary Figure 5n ). The transcriptional changes observed in Utx pKO mice are, therefore, directly relevant to a subset of human PDAC tumors.
UTX co-activates acinar differentiated cell programs.
To further understand the direct mechanisms whereby UTX regulates genetic programs relevant to PDAC, and the potential link to HNF1A, we integrated transcriptome changes in Utx pKO pancreas with profiling of UTX-bound genomic sites in pancreas from 4-day old mice. We identified 8455 UTX binding sites (Supplementary Figure 5o) , which were not detected when performing ChIP-seq in Utx pKO pancreas (Supplementary Figure 5p ). Most UTX binding sites were located in active enhancers and promoters (Supplementary Figure 5q) , and they were enriched in genes that were downregulated in Utx pKO mice, but not in those that showed upregulation (Figure 5e , Supplementary Figures 5p and 2g) . UTX was, consequently, preferentially bound near acinar-enriched genes, but not to genes involved in EMT or other pathways that showed induction in Utx pKO pancreas. This indicates that although UTX has been reported to have transcriptional activating and repressive functions 39 , the most prevalent direct function of UTX in pancreatic cells appears to be the transcriptional activation of gene targets, and indirect inhibition of many other genes.
UTX is a H3K27 demethylase, although previous studies have also demonstrated UTX functions that are independent from this catalytic activity 15, [39] [40] [41] [42] [43] . We observed that in the pancreas of Utx pKO mice, UTX-bound enhancer and promoter regions showed increased H3K27me3 (Figure 5f ), which was greatest in genes that showed significant downregulation in Utx pKO mice (Figure 5g, Supplementary Figure 5p ). Consistent with UTX forming part of complexes containing histone acetyl transferases p300/CBP 44-46 we also observed decreased H3K27ac in those regions in Utx mutants (Figure 5f,g Supplementary Figure  5p ). UTX-bound sites, therefore, often showed concomitant H3K27me3 gain and H3K27ac loss (Figure 5h) . Collectively, these results indicate that the direct function of UTX in pancreatic cells entails profound chromatin changes and transcriptional activation of genomic binding sites.
HNF1A and UTX share functional targets in acinar cells. UTX is not a sequence-specific DNA binding protein and the mechanism that recruits UTX to its genomic sites is poorly understood. We therefore examined UTX-bound sequences to identify candidate transcription factors (TFs) that recruit UTX in pancreatic cells, and specifically focused on the subset of UTX-bound sites associated with transcriptional changes in Utx pKO mice. These functional UTX-bound regions were enriched in in silico-predicted DNA-recognition sequences for canonical acinar TFs such as FOXA, GATA6, NR5A2 and RBPJL, although the most enriched sequence was the HNF1 recognition motif (Figure 6a) . Consistently, functional UTX-bound regions were enriched for in vivo binding sites for multiple acinar cell TFs, yet showed the highest enrichment for HNF1A binding (Figure 6b) . These findings, therefore, pointed to a strong overlap between UTX and HNF1A occupancy in pancreatic cells. Consistent with these findings, 31 of the 40 most downregulated genes in Utx pKO pancreas were also downregulated in Hnf1a aKO pancreas, or are known to be HNF1A-depdendent target genes (Figure 6c) . Accordingly, gene set enrichment analysis (GSEA) showed that genes that were significantly down-or upregulated in Utx pKO mice were preferentially down-or upregulated in Hnf1a aKO mice (Figure 6d, and Figure 6e for the converse comparison). This indicated that the derangement of shared biological pathways in Utx pKO and Hnf1a aKO mice (shown in Supplementary Figure 5k ) was largely due to deregulation of common genes. More specifically, UTX-bound genes that showed downregulation in Utx pKO mice were largely downregulated in the pancreas of Hnf1a aKO , (Figure 6f and 6g) . Importantly, UTXbound genes showed downregulation in Utx pKO if they were co-bound by HNF1A, but showed more marginal changes when they were not co-bound by HNF1A, suggesting that HNF1A could be critical for UTX function (Figure 6h) . Collectively, these findings indicate that HNF1A and UTX target common genomic sites and regulate shared gene programs in pancreatic acinar cells.
HNF1A recruits UTX to genomic targets in pancreatic cells.
To define the molecular mechanisms that link UTX and HNF1A function, we performed co-immunoprecipitation experiments using purified nuclei from a mouse acinar cell line. This showed that HNF1A and UTX form part of a common complex in pancreatic cells (Figure 7a) . To test whether this interaction could mediate the recruitment of UTX by HNF1A to its genomic targets, we performed ChIP-seq for UTX using chromatin from pancreas of wild type and Hnf1a -/mice. This showed that UTX binding to genomic targets was drastically reduced in Hnf1a -/pancreas (Figure 7b) . Importantly, regions with reduced UTX binding in Hnf1a -/pancreas were bound by HNF1A and carried HNF1 motifs (Figure 7c-e ). These findings, therefore, showed that HNF1A recruits UTX to genomic targets. Consistent with the functional importance of this recruitment, most genes associated with reduced UTX binding in Hnf1adeficient pancreas were direct HNF1A target genes with decreased expression in Hnf1adeficient pancreas (Figure 7f, Supplementary Figure 6a-e ). By contrast, HNF1A binding was not affected in Utx pKO pancreas, indicating that, despite the functional interdependence of both proteins, UTX is not required for HNF1A binding to chromatin (Supplementary Figure  6f) . These results, therefore, show that HNF1A interacts in a common complex with UTX, and recruits it to its functional targets in pancreatic cells. Collectively, these findings suggest a mechanistic model (Figure 7g ) that explains the overlapping genomic phenotypes of HNF1A-and UTX-deficiency in genetic mouse models and human tumors, and their contribution to determine PDAC subtypes.
Discussion
In this study we provide a direct genetic demonstration that HNF1A, which encodes for a homeodomain transcription factor best known for its causal role in autosomal dominant diabetes 47 , has a tumor suppressive function in the exocrine pancreas. We further provide epigenomic, biochemical and genetic evidence that mechanistically link HNF1A function in pancreatic exocrine cells to UTX, an established tumor suppressor. These results in turn indicate that the tumor suppressive function of UTX is tightly linked to its role as a transcriptional co-regulator of epithelial differentiation. We demonstrate that HNF1Adeficiency partially phenocopies UTX-driven tumorigenesis in mice, and show that HNF1A/UTX-deficiency is a prominent feature of the genetic programs of non-classical human PDAC tumors. These findings, therefore, shed light on mechanistic underpinnings of emerging sub-classification of PDAC subtypes.
Our analysis of Utx-deficient Kras G12D mice is consistent with a recent report showing aggressive PDAC in Utx-deficient Kras mutant mice 15 , and extend those studies by defining the genetic programs that are directly regulated by UTX in the differentiated pancreatic exocrine cells that give rise to PDAC. The UTX-deficient transcriptome phenotype observed in non-tumoral pancreas was consistent with that reported in tumors from Utx-deficient Kras mutant mice 15 . Our integrated analysis of genomic binding sites indicated that the positive regulatory effect of UTX (and HNF1A) on acinar differentiation genes are largely direct, whereas the suppression of oncogenic and EMT regulatory programs in pancreatic cells is predominantly indirect.
Our studies, therefore, exposed a molecular mechanism whereby HNF1A recruits UTX to activate differentiation programs of pancreatic exocrine epithelial cells, thereby suppressing oncogenic and EMT pathways (Figure 7g ). This mechanism aligns well with the observation that Utx-and Hnf1a-deficient tumors in mice featured sarcomatoid architecture. We further showed that HNF1A-and UTX-dependent pancreatic programs are defective in non-classical PDAC tumors, variously defined as human basal, quasi-mesenchymal or squamous molecular types 3, [35] [36] [37] 48 . Interestingly, abnormalities in the HNF1A/UTX dependent pancreatic program in tumors were associated with either somatic UTX mutations, or to decreased expression of UTX or HNF1A, in consonance with the proposed molecular mechanism.
These findings indicate that the disruption of HNF1A and UTX-dependent programs not only promotes the formation of PDAC, but is also instructive for the definition of PDAC subtypes. HNF1A is expressed in normal acinar cells, the presumed cell of origin of most PanIN precursors and PDAC 33, 34 , but not in duct cells. The results suggest that in the presence of other oncogenic events, defective HNF1A-, UTX-dependent gene regulation can promote the development of an undifferentiated high-grade PDAC cellular phenotype (Figure  7g) G12D 3 , Hnf1a -/-4 , and Ptf1a Cre 5 mouse lines have been described.
To generate a conditional Hnf1a allele, a floxed Hnf1a exon 2 was generated in C57Bl/6N JM8.F6 embryonic stem cells (ES cells) 6 by homologous recombination. Briefly, ES cells were electroporated with a targeting plasmid construct linearized by PmeI and MluI, containing the floxed exon and a PGK/Neomycin selection cassette flanked by FRT recombination sites, and then selected with Geneticin. Several correctly targeted ES cell clones were identified by Southern blot using external probes detecting a 9.2kb 5' ScaI fragment, an 8.7kb 3' BamHI fragment from the recombined allele and a neo probe detecting a unique 11.7 kb SpeI Neomycin fragment indicating no additional construct integrations. The presence of the distal LoxP site, upstream of exon 2, was confirmed by PCR using the primers indicated in Supplementary Table 6 . Correctly targeted ES cell clones were injected into C57BL/6BrdCrHsd-Tyrc morulae (E2.5) to create chimeric mice that transmitted the recombined allele through the germ line. The PGK/Neo cassette was excised by crossing heterozygous mice with Tg.CAG-Flp mice 7 , which express the FLPe recombinase in the germ line to create the Hnf1a conditional knockout allele. Lines with floxed alleles without Cre, Cre lines without floxed alleles, Pdx1 Cre ;LSL-KRAS G12D or wild-type littermates served as controls. Gender was considered as a variable and included in the study design. Genotype was confirmed by PCR using the primers provided in Supplementary Table 6 .
Prior to decapitation, mice were anesthetized using isoflurane (Zoetis), pancreas was collected quickly and placed in paraformaldehyde 4% (Sigma-Aldrich) for paraffin embedding or processed for RNA isolation.
Histology, TMA preparation and Immunohistochemistry. Fixation of mouse pancreas was performed using paraformaldehyde 4% (Sigma-Aldrich) or 4% buffered formalin overnight at 4 ºC followed by dehydration using increasing concentrations of ethanol. Dehydrated samples were embedded in paraffin blocks and cut in 4 µm sections. Sections were then deparaffinized and rehydrated. For hematoxylin and eosin analysis, the pancreata were stained, dehydrated, mounted with DPX (Panreac) and photo documented using optical microscopy (Olympus BX41TF).
Tissue samples for tissue micro arrays (TMAs) were obtained from patients who underwent pancreatic resection for PDAC (n=223) at the Department of Surgery of the University Hospital of Duesseldorf, Germany. The samples were fixed in 4% formalin and subsequently routinely embedded in paraffin. Three tumor samples per case (two samples from the tumor center, one from the periphery) with a 1-mm core size were selected and assembled into the TMA (Manual Tissue Arrayer MTA-1, Beecher Instruments, Inc., Sun Prairie, WI, USA). The use of human tissue samples was approved by the local ethics committee at the University Hospital of Duesseldorf, Germany (study number 5387). The TMAs were then cut in 2 µm sections for subsequent procedures.
Immunohistochemistry on mouse pancreas or TMAs, was performed according to manufacturer´s instructions using VectaStain® ABC HRP Rabbit IgG kit (Vector Laboratories, Peterborough, UK). Epitope retrieval was achieved by pretreatment with boiling citrate buffer (10 mM citric acid, pH6) for 15 min using a pressure cooker. Endogenous peroxidase and protein blocking was performed with 3% H 2 O 2 diluted in PBS for 10 min and with 1% BSA, 10% normal goat serum (Abcam, Cambridge, UK) and 0.1% Triton-X (Merck KGaA, Darmstadt, Germany) for 60 min. Anti-HNF1A and anti-UTX stainings were performed at a dilution of 1:250 (Anti-HNF1A, Abcam ab204306, Cambridge, UK), 1:200 (Anti-HNF1A, Cell Signaling Technology, 89670, Leiden, The Netherlands) and 1:100 (Anti-UTX, Cell Signaling Technology 33510S, Denver, USA), respectively. Diaminobenzidine (Abcam ab64238, Cambridge, UK) was used as chromogen to visualize protein expression, counterstaining was achieved with Mayer´s hemalaun solution (Merck KGaA, Darmstadt, Germany).
Analysis of TMAs.
The semi-quantitative analysis of the stained sections was done by lightmicroscopy according to the immunoreactive score (IRS) of Remmele and Stegner 8 . Both the staining intensity and the number (%) of positive stained cells were evaluated for each case. If more than one tumor core was available in one case, a mean value was calculated. Staining intensity was scored as no staining (0), weak staining (1), moderate staining (2) or strong staining (3) . The proportion of stained cells was scored as follows: no staining=0, 1-9%=1, 10-50%=2, 50-80%=3, >80%=4. The IRS was calculated by multiplication of the intensity value and the percentage value, resulting in a score between 0 and 12. Finally, IRS results were classified into four groups as follows: 0-1=negative (group 0), 2-3=weak (group 1), 4-8=moderate (group 2), 9-12=strong (group 3). Each tumor case was graded according to UICC and WHO classifications. Two cases with undetermined grade (Gx) were omitted from the analysis. The rest of the cases were either scored as G2 or G3 grades. Contingency table analysis and Chi-square test were used to evaluate the association between IRS classifications and tumor grades.
Immunofluorescence. Immunofluorescence analysis of murine pancreata was performed on paraformaldehyde-fixed paraffin-embedded tissue cut into 4 µm sections, as described with modifications 9 . Antigen unmasking was performed boiling sections on 10 mM citrate buffer pH 6 for 10min and tissue was permeabilized with PBS 0.5% Triton X-100 (Sigma). Blocking was performed by 1h incubation in humid chamber with 3% of normal donkey serum (Vendor) in blocking solution (DAKO). Slides were incubated in humid chamber with primary antibodies overnight at 4ºC and washed in PBS 0.2% Triton-X100. Slides were incubated with secondary antibodies for 1h in humid chamber at room temperature, washed for 5 min in PBS 0.2% Triton-X100 and mounted using fluorescence mounting medium (DAKO). Stained slides were analyzed using a confocal laser scanning microscope (Leica CTR6500). Primary antibodies used are indicated in Supplementary Table 7 .
Western blotting and co-immunoprecipitation. All protein isolation steps were performed at 4 °C or on ice and protein concentrations were assessed with the Bradford assay (Bio-Rad). Protein from total pancreas lysates was isolated from a small fragment of mouse pancreas and minced in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 , 1 µg/ml leupeptin containing 1x phosphatase inhibitor cocktail, Sigma-Aldrich and 4 x EDTA containing complete protease inhibitor cocktail, Roche). Lysates were freeze-thawed twice, cleared at 15000 g for 15 min and then the supernatant was recovered. For Western blots, lysate supernatants were denatured in 2X NuPAGE LDS sample buffer (Thermo Fisher) containing 0.1 M DTT at 95 °C for 5 min. Equal amount of lysates were loaded in NuPAGE 4-12% Bis-Tris Protein Gels (Life Technologies) and run at 150v for 90min. Gels were transferred to 0.2μm pore PVDF membrane (Life Technologies) and blocked with 5% fat-free milk powder for 60 min and probed overnight (ON) with primary antibody. Horseradish peroxidase conjugated secondary antibodies were used at 1:10,000 in BSA 5% and incubated 1h at RT. The blot was developed using ECL detection reagent (Amersham ECL, GE Healthcare). The pancreatic acinar cell line 266-6 (ATCC CRL-2151) was grown in DMEM (Thermo Fisher) with 10 % fetal calf serum, 1 % pen/strep and passaged twice per week. For co-immunoprecipitation, the cells were washed in ice-cold PBS and resuspended in hypotonic lysis buffer (10 mM HEPES, pH 7.9, with 1.5 mM MgCl 2 and 10 mM KCl). After plasma membrane disruption, the lysate was centrifuged at 4000g for 5min and the nuclei lysed for 20min with gentle shaking in nuclear extraction buffer (20 mM HEPES, pH 7.9, with 1.5 mM MgCl 2 , 0.42 M NaCl, 0.2 mM EDTA, and 25% (v/v) Glycerol) before removing cell debris by centrifugation at 15,000g for 15 min. The cleared nuclear lysate was equilibrated to 150 mM NaCl, pre-cleared with Dynabeads Protein G (Thermo Fisher) for 1 h at 4 °C with rotation and 4 mg of extract was incubated overnight with 2 µg of anti-Utx, anti-HNF1A or normal rabbit IgG. Immune complexes were precipitated with 20 µl Dynabeads for 2 h and washed four times with IP wash buffer (10 mM Tris-HCl, pH 8, 150 mM NaCl, 0.1% NP-40 and 1 mM EDTA) supplemented with protease inhibitor. Proteins were eluted with 2X NuPAGE LDS sample buffer (Thermo Fisher) containing 0.1 M DTT at 95 °C for 5 min, and analyzed by western blotting.
RNA isolation.
For gene expression profiling we implemented a method for purification of intact pancreatic RNA according to a modified Guanidinium salts method 10 . Briefly, a small piece of pancreatic tissue was immediately homogenized with a Polytron (VWR) in precooled 4 M Guanidinium Thiocyanate with 112 mM beta-mercaptoethanol, centrifuged at 5000g for 5 min at 4°C to remove insoluble debris. RNA was precipitated from the supernatant with pre-cooled 75% Ethanol, 0.1M potassium acetate, pH 5.5, and 75mM acetic acid at -20 °C for 2 hr. The precipitate was pelleted by centrifugation at 10,000g for 10 min at 4 °C and resuspended at room temperature in 7.5 M Guanidinium HCl and 10.5 mM betamercaptoethanol. The RNA was re-precipitated twice with 0.1 M potassium acetate, pH 5.5, and 50% ethanol to remove residual RNAses, followed by purification with TRI Reagent RNA Isolation Reagent (Sigma-Aldrich). The concentration and quality of RNA was measured with a NanoDrop spectrophotometer (ND-1000, Thermo Scientific) and an Agilent 2100 Bioanalyzer. RNA integrity numbers ranged from 7.8 to 9.3. Alternatively, we used a previously described protocol 11 .
RNA-seq. One μg of total RNA was used to make RNA-seq libraries using the Truseq Stranded mRNA Sample Prep Kit (Illumina) following manufacturer's instructions and sequenced by an Illumina HiSeq2500 platform with single-end reads of 50 bases. Conversion to FASTQ read format was done using Illumina's bcl2fastq algorithm. Four or three pancreases from, respectively, 4 days old or adult female mice of each genotype were analyzed: Utx LoxP/LoxP and Pdx1 Cre ;Utx LoxP/LoxP or Ptf1a Cre and Ptf1a Cre ;Hnf1a LoxP/LoxP . Raw RNA-seq reads were aligned to the mouse transcriptome (a combined build of cDNA and ncRNA from Mus musculus v.GRCm38.p5, release 87) and quantified using Salmon v0.7.2 12 , with the following parameters: salmon quant --gcBias, --libType A and --fldMean and --fldSD . The latter two were set to the average size and standard deviation of the fragment length distribution of the given library, respectively. The counts were used in DEseq2 (v1.14.1) 13 with R (v3.3.3) 14 for normalization and identification of significant differential expression (q<0.05) between controls (n=4) and mutants (n=4). Only genes with log2 (basemean) > 2.5 were retained for downstream analysis. For visualization, STAR (v2.3.0) 15 was used to align reads to the mouse genome assembly GRCm38.p5 (mm10) and resulting BAM files were converted to bigwig with reads per genomic content (RPGC) normalization by Deeptools (v2.4.2) 16 .
ChIP sequencing.
ChIP experiments were performed on pancreas from day 4 old or 3 weeks old female mice. A Polytron was used to quickly mince 1-2 dissected pancreas in PBS with protease inhibitors followed by crosslinking with 1% formaldehyde for 10min at room temperature on a rotator and then quenched with 0.125M glycine for 5min. Tissue pieces were washed in PBS and lysed in 130 µl lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris-HCl, pH 8.0, 1 mM EDTA) with protease inhibitor on ice for 10 min and finally resuspended with a 30G needle syringe. The chromatin preparation was then sonicated to fragments enriched in the size range of 150 to 500 bp using S220 Focused Ultrasonicator (Covaris) and centrifuged at 14000 rpm for 10 min at 4 °C to pellet insoluble material. The supernatant was incubated for 1 h with 350 µl RIPA-LS buffer (10 mM Tris-HCl, pH 8.0, 140 mM NaCl, 1mM EDTA, pH 8.0, 0.1% SDS, 0.1% Na-Deoxycholate, 1% Triton X-100) with protease inhibitor and 20 µl Dynabeads Protein G for pre-clearing. After preserving 1% as an input sample the pre-cleared chromatin was incubated with 2 µg antibody, 50 µl 10% BSA and 5 µl tRNA (10 mg/ml) overnight at 4 °C with rotation. Immune complexes were retrieved with 20 µl BSA blocked Dynabeads Protein G for 2 h and washed 2x with RIPA-LS, 2x with RIPA-HS (10 mM Tris-HCl, pH 8.0, 500 mM NaCl, 1mM EDTA, pH 8.0, 0.1% SDS, 0.1% Na-Deoxycholate, 1% Triton X-100), 2x with RIPA-LiCl (10 mM Tris-HCl, pH 8.0, 250 mM LiCl, 1mM EDTA, pH 8.0, 0.5% IGEPAL, 0.5% Na-Deoxycholate) and 1x with 10 mM Tris, pH 8.0. Libraries were then prepared directly on the bead-bound chromatin according to a ChIPmentation procedure that is optimized for low cell number samples 17 ChIP-seq alignment and peak calling. ChIP-seq reads were aligned to the mouse genome (M. musculus, UCSC mm10) using Bowtie2 followed by exclusion of mapping quality scores < 30 by Samtools (v1.2) 18 and removal of duplicate reads with Picard (v2.6.0) and blacklisted regions with Bedtools (v2.13.3) 19 . The processed BAM files were converted to bigwig files using Deeptools. Peaks for histone marks were called with MACS2 (v.2.1.0) with settings: --extsize=300 --q 0.05 --keep-dup all --nomodel --broad and for Utx and transcription factors with MACS1.4 (v1.4.2) using default parameters and P<10 -10 . Enriched regions were scored against matching input libraries. All experiments were done as biological replicates. For histone marks and UTX ChIPs only enriched regions that overlap in replicates were retained as consistent peaksets. Publically available datasets were processed identically. For HNF1A ChIPs, peaks from two replicates that overlap by at least one base were merged and replaced with a single peak. Library information of public and internal datasets is provided in Supplementary Table 8 .
Integrative analysis. Active promoters were defined as consistent H3K27ac peaks occurring within 1kb of an annotated transcription start site (GENCODE GRCm38.p5) and all remaining peaks were considered as active enhancers. HNF1A and UTX peaks were annotated with HOMER (v4.10.3) 20 to define TSS-proximal, TSS-distal, intronic, exonic, and intergenic regions, and were assigned to genes using the "closest" function in Bedtools with default parameters. Fisher's exact test in R was used to define enrichment of HNF1Aand UTX-bound regions and active promoter and enhancer regions, or differentially expressed genes in the Hnf1a aKO and Utx pKO datasets. Expressed genes (Log2 TPM>2.5) were used as background. Aggregation plots were calculated with Deeptools. Briefly, all Utx bound regions were extended ±10 kb or ±5 kb from the center of the peaks for analysis of H3K27me3 or H3K27ac signals, respectively. The resulting regions were then divided into 10 bp bins and the mean value in each bin was calculated based on the normalized values given in the bigwig files for the histone marks. To assess the relationship between functional UTX binding sites and UTX-dependent histone modification changes, the Log 2 fold change of the averaged normalized H3K27me3 signals were plotted against the Log 2 fold change of H3K27ac signals in each Utx-bound region. Differential binding of UTX and HNF1A was analyzed with DiffBind (v2.6.6) 21 using the DEseq2 method without control input read counts. Differential peaks with FDR<0.05 were defined as significant.
Functional Annotation and Gene Set Enrichment Analysis (GSEA).
The ENRICHR tool 22, 23 was used to functionally annotate differentially expressed genes. Significantly enriched signatures were identified using Bonferroni corrected P<0.01. The GSEA pre-ranked analysis 24 was used to determine whether predefined sets of genes show significant concordant differences with gene expression changes in RNA-seq datasets. For GSEA we used gene sets from the Molecular Signature Database 25 , custom made sets of differentially expressed genes from our dataset, gene sets of pancreatic cell types 26 , and human PDAC [27] [28] [29] . All were analyzed with the parameters: numbers of permutations = 10000 and scoring scheme = weighted.
Motif Analysis. To find enriched de novo transcription factor DNA-binding profiles we used HOMER 20 and searched for 6, 8, 10, and 12 bp sized motifs in ±250bp regions surrounding the center of Utx -bound regions within promoters and enhancers that were functionally associated with transcriptional changes. As background sequences we used all H3K27ac regions. DNA-motifs were annotated with HOMER and retrieved if the HOMER score was more than 0.7. Centrimo from the MEME suite 30 was used to compute enrichment of known HNF1A motifs in HNF1A-bound regions (Supplementary Figure 2g) and in UTX-bound regions (Figure 7d) . Position weight matrices for HNF1 were retrieved from JASPAR 31 (http://jaspar.genereg.net/) and HOCOMOCO 32 (http://hocomoco11.autosome.ru/) databases. Data Visualization. Bigwig files from RNA-seq and DNA-seq experiments were visualized in the Genome Browser (http://genome.ucsc.edu/). R packages were used to create boxplots (BoxPlotR) 33 , bar and scatter plots (ggplot2) 34 . Enrichment plots from GSEA were drawn by Genepattern 35 . Aggregation plots and heatmaps of ChIP experiments were drawn with Deeptools. GraphPad Prism 6 was used for bar graphs, calculation of contingency tables and piecharts. To draw heatmaps we used Morpheus (https://software.broadinstitute.org/morpheus).
Analysis of human PDAC genomic data
Data acquisition and preprocessing. RSEM normalized RNA-seq data from the TCGA-PAAD cohort was downloaded from the Firehose browser (https://gdac.broadinstitute.org/). Molecular subtypes and purity class was assigned to each sample as defined by the Cancer Genome Atlas Research Network 36 . Samples with high purity (76 samples) were retained for further analysis. Quantile normalized background adjusted array expression data from the ICGC-PACA-AU cohort was downloaded from the ICGC data portal (https://dcc.icgc.org/). Probe sets (ILLUMINA HumanHT 12 V4) were assigned to gene names. Multiple probe sets mapping to the same gene were collapsed using the collapseRows algorithm from the WGCNA package 37 keeping the gene-probe set combination with highest variance across all samples. Purity class was assigned to each sample according to Bailey et al. 27 retaining 121 high purity samples for further analysis.
Consensus clustering.
Samples from the ICGC-PACA-AU study were classified into molecular subtypes based on signature genes from Collisson et al. 28 , Moffitt et al. 29 , or Bailey et al. 27 . Out of the 62 PDA assigner genes identified by Collisson et al., 57 matched with our preprocessed data. We also selected 50 genes with the highest gene weights for the basal and classical PDAC subtypes (100 genes in total) from Moffitt et al's gene factorization analysis, out of which 94 genes matched with our data. From Bailey et al.'s 613 differentially expressed genes across their defined classes (Squamous, ADEX, Immunogenic, and Pancreatic Progenitor), we retained 457 matching genes. We then applied consensus clustering to the ICGC-PACA-AU data with the signature genes from the three studies using ConsensusClusterPlus (CCP) v.1.24.0 38 . Each gene expression profile was first Log 10transformed and median centered. We next performed 1000 iterations of CCP using Pearson correlation as the distance metric, partitioning around medoids, and a random gene and sample fraction of 90% in each iteration. We verified that the obtained groups and their gene expressions reflected the up and down relationships for each gene in each group described in the three studies. We next used human orthologs of differentially expressed genes from our study in Hnf1a-deficient mouse pancreas to cluster the TCGA-PAAD and ICGC-PACA-AU cohorts. We applied consensus clustering with non-negative matrix factorization, using Pearson distance metrics and 2000 descent iterations 39 , and thereby identified a group of samples with similar expression signature to the Hnf1a aKO pancreas. To generate expression heatmaps, we identified genes that were differentially expressed across the clusters (FDR<0.05) with a SAM multiclass analysis (samr v.2.0) 40 , Z-score transformed each row of the matrix, then used Morpheus (https://software.broadinstitute.org/morpheus) to cluster only the rows, using a one minus Pearson correlation distance metric, average linkage method and Hierarchical clustering.
To identify tumors with most pronounced HNF1A-deficient function, we first defined a gene set containing 106 human orthologs of HNF1A-bound genes that were downregulated in Hnf1a aKO mouse pancreas. We then interrogated that behavior of this gene set in every tumor sample. This was carried out by GSEA (see also GSEA subheading), using the HNF1Adependent gene set, and testing the enrichment in each tumor's gene lists rank-ordered by differential expression of all genes in the tumor vs the median expression of all genes across all samples. This analysis revealed 3 groups of tumor samples: (1) HNF1A loss-of-function (LoF) with NES<0, P<0.05, (2) Control 1 with NES<0, P>0.05, and (3) Control 2 with NES>0.
UTX mutations. Information on UTX mutations was retrieved from the ICGC data portal (https://dcc.icgc.org) and Bailey et al. 27 . 15 samples in the high-purity ICGC-PACA-AU cohort had UTX mutations, which we separated into 3 groups according to mutation types defined by ICGC: (1) Deletions (small <=200bp), (2) Substitutions (single base), (3) Insertions (small <=200bp. The fourth group, (4) Structural Variants, were from Bailey et al.
Mutations defined by ICGC as having ´high´ functional impact in (1) (2) (3) and having a ´loss of function´ consequence in (4) were all frame-shift mutations. We considered those mutations as being functional deleterious and defined samples with such genetic alterations in UTX as UTX loss-of-function (LoF) tumors. The rest were defined as samples with UTX mutations of unknown consequence. Significantly Mutated Genes (SMGs) were from Bailey et al.'s 27 SMG analysis using Intogen, Mutsig and HOTNET. Genes considered significantly mutated were significant in >1 analysis.
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Wilkerson Figure  1n ) whereas at the same age pancreas from Utx pKO ;Kras G12D mice show massive remodeling (k), extensive acinar-to-ductal metaplasia (l and dashed encircled area in n), cancer with prominent spindle/mesenchymal proliferation, infiltrative growth (asterisk and black arrows in o) and abundant stroma (black arrowheads in n). Scale bars100 µm (b,d,e,j,k) or 20 µm (c,f,g-i, l-n).
Figure 5. UTX promotes acinar cell differentiation gene programs and suppresses oncogenic pathways. a, Fold change (FC) in transcripts in
Utx pKO vs. control pancreas, plotted against significance (-Log 10 q; genes significant at q<0.05 are shown as colored dots above the horizontal line). b, GSEA showing that genes specific to differentiated acinar cells were downregulated in UTX-deficient pancreas, but not genes specific to islets or duct cells. Upregulated genes were enriched in genes specific to mesenchymal cells. Lineage-enriched genes were obtained from Muraro et al. 1 c, Functional annotation of most enriched processes in genes differentially expressed in Utx pKO . d, GSEA showed increased expression of indicated oncogenic pathway genes in Utx pKO pancreas. e. UTX functions as a transcriptional activator of direct target genes in pancreatic cells. Left: Downregulated, but not upregulated, genes in Utx pKO pancreas were enriched for UTX binding. P-values and odds ratios (O.R.) were calculated by Fisher's exact test. Right: Venn diagrams showing overlap of down and upregulated genes with UTX binding. f, Aggregation plots of H3K27me3 and H3K27ac signals in UTX-bound enhancers and promoters show increased H3K27me3 and decreased H3K27ac in Utx pKO relative to control pancreas. g,h, UTX-bound genes that showed decreased expression in Utx pKO pancreas (functional UTX binding sites) showed simultaneous gain of H3K27me3 and loss and of H3K27ac. P-values in (g) were determined by two-tailed Mann-Whitney U test. Figure 6 . UTX and HNF1A regulate shared target genes. a, Motif analysis in functional UTX-bound regions, showing top ten de novo motifs ranked by P-value determined by HOMER software. b, Co-binding analysis in functional UTX-bound enhancer and promoter regions revealed that HNF1A was the most enriched co-bound TF amongst three other acinar cell TFs. Binding regions of TAL1 in a non-pancreatic cell type and random binding sites were used as negative controls. P-values was determined by Fisher's exact test for peak comparisons using all enhancer and promoter regions as background. c, The most downregulated genes in Utx pKO pancreas are shown ranked by q-value, and are almost invariably bound by HNF1A and down regulated in Hnf1a aKO pancreas, or known to be direct HNF1A-dependent target genes from other studies (red and purple, respectively). d,e, GSEA analysis on the Hnf1a aKO and Utx pKO ranked-ordered gene lists vs. their reciprocal up-or downregulated gene sets, demonstrated that UTX and HNF1A regulate similar genes. f, Scatter plot showing expression changes of Hnf1a aKO and Utx pKO genes. Genes that were bound by UTX and downregulated in Utx pKO pancreas (functional UTX targets; red dots) were downregulated in Hnf1a aKO pancreas. g, Example showing that HNF1A and UTX cooccupy the same regions in the Pah gene. In Hnf1a or Utx knock-out pancreas, Pah expression is downregulated. h, Genes that were co-bound by UTX and HNF1A showed greatest downregulation in Utx pKO pancreas as compared with UTX bound genes that were not bound by HNF1A depicted as box plots with median and interquartile range of Log 2 foldchanges in TPM values. P-values were determined by two-tailed Student's t tests. Figure 7 . HNF1A recruits UTX to activate transcription of its target genes. a, Coimmunoprecipitation experiment of endogenous HNF1A and UTX followed by western blot demonstrated that HNF1A is in the same complex as UTX. b, Differential binding analysis of UTX in Hnf1a -/vs. wild type pancreas. Pink dots below zero (1873 sites) show regions with reduced UTX binding and pink dots above zero (118 sites) are regions with increased binding at FDR<0.05. c,d, Regions that show reduced Utx binding in Hnf1a -/chromatin are strongly bound by HNF1A and are highly enriched in HNF1 motifs. P-values in (c) were calculated with two-tailed Mann-Whitney U test and in (d) with Fisher's exact test. e, UTX binding is markedly reduced in HNF1A and UTX co-bound regions in Hnf1a -/pancreas, but not in other UTX bound regions. f, Genes that loose UTX binding in Hnf1a-mutant pancreas are predominantly downregulated in Hnf1a aKO pancreas and are direct HNF1A target genes (red dots). g, Summary model depicting that HNF1A recruits UTX to genomic binding sites to activate an acinar differentiation program that indirectly suppresses core oncogenic pathways.
In the presence of KRAS mutations and other oncogenic events, defective HNF1A or UTX function results in failure of this shared program, with increased activity of pathways that promote high-grade non-classical PDAC.
